The HemOnc Pulse Live: MPN
Stay tuned for exclusive MPN discussions and follow #HOPlive24 on X for the live updates from the meeting.
Advertisement
Advertisement
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.